LAT CAB Brochure

By Ana Balkandjieva

1 February 2023

Long-acting technologies

Learn about LAT CAB, Longevity project and meet the LAT CAB community experts.

Attached documents

LAT CAB Brochure

PDF – 656.7 KiB

Related materials

About

LAT CAB reviews the state of treatment research, contributes to research protocols, and engages in the research and development process for long-acting technologies for malaria, HCV, and LTBI. More

23 January 2024CABs LAT CAB (2021-present)

Illustrated Glossary for LATs

The Glossary compiles frequent terms and concepts used in the research and development of long-acting technologies. More

19 September 2021CABs LAT CAB (2021-present)

Medicines Patent Pool Secures its First Licence on Promising Long-Acting Technologies for Malaria, TB, and Hepatitis C

The licence covers the patents and expertise of promising long-acting injectable technologies that could be applied in three disease areas with a high prevalence in LMICs. More

21 September 2021CABs LAT CAB (2021-present)

TAGline: Delivering on the Promise of Long-Acting Formulations

October 2021 issue of TAGline delves deep into the development of long-acting formulations for the treatment and prevention of HIV, TB, hepatitis C, and malaria. More

7 October 2021CABs LAT CAB (2021-present)

Hepatitis C and TB Long-Acting Medicines: Analysis of Patenting Trends and Implications for Access

A patent landscape, released by TAG, investigates potential patent barriers for the development and delivery of long-acting formulations for selected hepatitis C and TB medicines. More

14 November 2021CABs LAT CAB (2021-present)

Call for New Global Long-Acting Technologies CAB Members from Asian, Central African, Eastern European, MENA, and Latin American Countries

TAG and AfroCAB announce an expanded call for a new cross-disease LAT CAB focused on malaria, hepatitis C, and latent TB. Apply now! Applications accepted on a rolling basis. More

24 January 2022CABs LAT CAB (2021-present)